



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-IL-4 [SB240683 (Pascolizumab, humanized 3B9)] Standard Size Ab02326-3.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2b, Fc Silent™, Kappa

**Clone Number:** SB240683 (Pascolizumab, humanized 3B9)

**Alternative Name(s) of Target:** IL4; BSF-1; Interleukin-4; B-cell stimulatory factor 1; Binetrakin; Lymphocyte stimulatory factor 1; Pitrakinra

**UniProt Accession Number of Target Protein:** P05112

**Published Application(s):** ELISA, Inhibit, functional assay, therapeutic, Block

**Published Species Reactivity:** cynomolgus monkeys, Human

**Immunogen:** The original mouse antibody was generated by immunizing F1 hybrids of Balb/c and C57BL/6 mice with recombinant human IL-4 in Freund's complete adjuvant. The humanized version was generated by grafting CDRs of murine parent antibody onto human IgG1 kappa heavy- and light-chain frameworks.

**Specificity:** This antibody binds human and cynomolgus monkey IL-4 and does not cross react with IL-4 from mouse, rat, cow, goat or horse. It does show binding to glycosylated interleukin-4. Interleukin-4 is a receptor for both interleukin 4 and interleukin 13. It couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.

**Application Notes:** The original mouse version of this antibody can recognize recombinant human IL-4 in an ELISA and is also capable of inhibiting IL-4 dependent T-cell proliferation in vitro (PMID: 7517357). Binding of this humanized antibody completely blocks the binding of IL-4 to IL-4R. An in vitro study demonstrated that pascolizumab effectively neutralized IL-4 bioactivity in human cell lines including inhibited the proliferation of human T cells, human B cells and TF-1 cells, inhibition of interleukin-4-dependent IgE production by human PBMCs and up-regulation of FcεRII. It also inhibited the early events of asthma including TH2 cell differentiation, eosinophilia and IgE up-regulation. In vivo pharmacokinetic and chronic safety testing in cynomolgus monkeys demonstrated that pascolizumab was well tolerated without

inducing adverse clinical responses (PMID:12296858). The pharmacokinetics of the human version of this antibody in the male Sprague Dawley rat was studied and the half life of the antibody was determined to be 11 days (US5914110A). A Phase I trial with a single intravenous dose in mild to moderate asthma demonstrated that it was well tolerated and had an elimination half-life of more than 2 weeks (Shames et al., 2001). However, a subsequent large-scale, multidose phase II trial in steroid-naive subjects with asthma was terminated because preliminary data showed that pascolizumab did not provide clinical benefit (clinical trials: NCT00024544).

**Antibody First Published in:** Hart et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol. 2002 Oct;130(1):93-100. [PMID:12296858](#)

**Note on publication:** The preclinical safety and efficacy of humanized version of anti-IL-4 antibody 3B9 (SB240683, Pascolizumab) was tested.

## Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.